Biosimilars/News

Production of 24 biogeneric products in Iran by 2012

Biosimilars/News | Posted 03/02/2012

According to reports on Iran’s English-language television network, Press TV, Iran is making significant advances in biogeneric products and biotechnology drugs and is planning to start the production of 24 additional biogeneric products drugs by the end of 2012.

Amphastar and Watson launch biosimilar enoxaparin

Biosimilars/News | Posted 03/02/2012

US generics manufacturer Watson Pharmaceuticals announced on 26 January 2012 that Amphastar Pharmaceuticals and Watson had been granted their request for a stay of the preliminary injunction preventing the companies from marketing or selling Amphastar’s enoxaparin sodium injection.

Sandoz starts phase III trials for biosimilar filgrastim and pegfilgrastim

Biosimilars/News | Posted 27/01/2012

On 19 January 2012, Sandoz, the generic drug division of Swiss drug giant Novartis AG, announced that it had started two phase III clinical trials, one for biosimilar filgrastim (Amgen’s Neupogen) for the US market and the other for its global pegfilgrastim (Amgen’s Neulasta) development programme.

Roche encounters manufacturing issues with epoetin-beta

Biosimilars/News | Posted 27/01/2012

The Spanish regulatory agency has found deviations in the quality of the manufacture of Switzerland-based F. Hoffmann-La Roche’s biological anaemia treatment Mircera (methoxy polyethylene glycol-epoetin beta), a long acting erythropoiesis-stimulating agent; and is recommending patients to change to other epoetins.

Baxter and Momenta make biosimilars deal

Biosimilars/News | Posted 20/01/2012

Baxter International (Baxter) and Momenta Pharmaceuticals (Momenta) announced on 22 December 2011 that they had entered into a global collaboration agreement to develop and commercialise biosimilars.

Amgen finally jumps on biosimilars bandwagon

Biosimilars/News | Posted 13/01/2012

Biotech giant Amgen and US generics manufacturer Watson Pharmaceuticals (Watson) announced on 19 December 2011 that the two companies had agreed to collaborate on the development and commercialisation of several cancer antibody biosimilars.

Hospira starts phase III programme for biosimilar erythropoietin

Biosimilars/News | Posted 13/01/2012

Hospira, self-proclaimed leader in injectable generics, announced on 9 January 2012 that the company had enrolled the first patient in its phase III programme in the US for its biosimilar erythropoietin (EPO).

First biosimilar G-CSF in Japan

Biosimilars/News | Posted 13/01/2012

Mochida Pharmaceuticals (Mochida) and development partner Fuji Pharma announced on 26 December 2011 that they had filed respective applications for the first biosimilar granulocyte colony-stimulating factor (G-CSF) in Japan.

Samsung makes biosimilars deal with Biogen Idec

Biosimilars/News | Posted 16/12/2011

Korean electronics giant Samsung announced on 6 December 2011 that it had entered into a biosimilars joint venture with US biotechnology company Biogen Idec (Biogen).

Indian Transgene sells biosimilar to German TSS Export

Biosimilars/News | Posted 09/12/2011

India-based biotech company Transgene Biotek Limited (Transgene) announced on 24 November 2011 the sale of technology for biosimilar recombinant human erythropoietin (rh-EPO) to TSS Export GmbH FZE, part of the Germany-based TSS group, for US$5 million (Indian Rupees 260 million).